Product Center
Steadily promoting national recruitment and supplementation standards, the first and only trivalent influenza virus subunit vaccine for the entire population helps global 2026 influenza prevention and control!
- Categories:Company news
- Author:
- Origin:
- Time of issue:2026-04-14
- Views:
(Summary description)Recently,Ab&B Bio-Tech Co., Ltd. JS (hereinafter referred to as "Ab&B Bio") once again received good news in the market. The domestically developed first and only all population, full dose trivalent influenza virus subunit vaccine (HRK-X® 3) has successfully won the bid for the non immunization plan vaccine procurement projects in Shanxi Province and Gansu Province, and once again won the bid for the 2026 Yunnan Province and Fujian Province non immunization plan vaccine supplementary procurement project at a price of 298 yuan/dose.
Steadily promoting national recruitment and supplementation standards, the first and only trivalent influenza virus subunit vaccine for the entire population helps global 2026 influenza prevention and control!
(Summary description)Recently,Ab&B Bio-Tech Co., Ltd. JS (hereinafter referred to as "Ab&B Bio") once again received good news in the market. The domestically developed first and only all population, full dose trivalent influenza virus subunit vaccine (HRK-X® 3) has successfully won the bid for the non immunization plan vaccine procurement projects in Shanxi Province and Gansu Province, and once again won the bid for the 2026 Yunnan Province and Fujian Province non immunization plan vaccine supplementary procurement project at a price of 298 yuan/dose.
- Categories:Company news
- Author:
- Origin:
- Time of issue:2026-04-14 11:25
- Views:
Recently,Ab&B Bio-Tech Co., Ltd. JS (hereinafter referred to as "Ab&B Bio") once again received good news in the market. The domestically developed first and only all population, full dose trivalent influenza virus subunit vaccine (HRK-X® 3) has successfully won the bid for the non immunization plan vaccine procurement projects in Shanxi Province and Gansu Province, and once again won the bid for the 2026 Yunnan Province and Fujian Province non immunization plan vaccine supplementary procurement project at a price of 298 yuan/dose.
This series of consecutive winning bids not only continuously verifies the agile action capability of Ab&B Bio's commercialization team in the face of market changes, but also fully demonstrates the company's stable performance realization ability. With the continuous expansion of product access coverage, Ab&B Bio will provide safer and higher quality vaccines to a wider population during the 2026-2027 influenza season, safeguarding public health.
With the official release of the recommended components for seasonal influenza vaccines in the Northern Hemisphere for 2026-2027 by the World Health Organization (WHO), influenza vaccines may usher in a "trivalent era".
Ab&B Bio, with its keen industry insight and strong ability to transform achievements, forward-looking layout, and precise pace, has brought the first and only trivalent influenza virus subunit vaccine for the whole population and full dose in China to the market. This product, together with the company's already launched quadrivalent influenza virus subunit vaccine, forms a "quadrivalent+trivalent" high-end influenza vaccine product dual line of defense, achieving seamless integration with policy trends and providing the market with more accurate and safer new protection options.
As a third-generation influenza vaccine, HRK-X® 3 only extracts the surface core antigen (HA/NA) of the virus, removes internal impurities of the virus, has higher purity, lower adverse reactions, better safety, and better immune efficacy. Phase III clinical data shows that local adverse reactions are lower in the split vaccine group compared to the control group. Full dose vaccination can provide stronger immune protection for infants and young children, and has good safety. At the same time, HRK-X® 3 has made a breakthrough in achieving unified vaccination of 0.5ml dosage form for the entire population aged 6 months and above, with infants and adults receiving the same dose of protection, greatly simplifying the vaccination process and bringing more convenient and efficient operating experience to medical staff.
At present, Ab&B Bio is accelerating the market access work of trivalent influenza virus subunit vaccine (HRK-X® 3), actively expanding the coverage area, ensuring the continuous delivery of high-quality influenza vaccines to more provinces (cities), strengthening the public immunity barrier, and allowing more families to enjoy professional and reassuring health protection.
Relevant information
-
Phase I/II Clinical Trial of the Re engineered Respiratory Syncytial Virus Vaccine (CHO Cells)(Adjuvant)Officially LaunchedOn May 13, the launch meeting for the Phase I/II clinical trial of the recombinant respiratory syncytial virus vaccine (CHO cell-based) (adjuvant) independently developed by Ab&B Bio-Tech CO.,LTD.JS. (Ab&B Bio) was successfully held at the research site in Sichuan. - The mRNA technology platform has achieved another milestone, with global innovation efforts accelerating. 05-08
- Our innovative vaccine research team won the 20th "Jiangsu Youth May Fourth Medal Collective" award 04-27
- The Ab&B Bio Promotion Business Conference and 10th Anniversary Celebration were successfully held 04-25
- Steadily promoting national recruitment and supplementation standards, the first and only trivalent influenza virus subunit vaccine for the entire population helps global 2026 influenza prevention and control! 04-14
Got a project? Contact us today !
At Ab&B Bio, our mission is to care for life and protect health by developing globally innovative vaccines.
Contact
E-mail:haixin.zhang@yitherbiotech.com
Add:No. 32, Xinglin Road, Medical High-tech Zone, Taizhou City
Quick view
Follow us
